Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.20.2
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Revenue from contract with customer $ 7,000     $ 5,000     $ 31,000 $ 35,000  
Grant and other revenue 261,616     231,916     664,848 514,589  
Revenues, Total 268,389     236,811     695,762 538,527  
Cost of revenue 82     195     1,048 6,559  
Research and development expenses 1,377,998     1,801,558     3,659,046 3,612,783  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,773,532     1,485,207     4,894,778 5,001,818  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 15,402     34,289     51,501 107,794  
(Loss) income from operations (3) [3] (2,898,625)     (3,084,438)     (7,910,611) (8,190,427)  
Other expense (4) [4] (713)     10,334     12,045 17,456  
Net (loss) income (2,899,338) $ (2,325,619) $ (2,673,608) (3,074,104) $ (2,673,179) $ (2,429,061) (7,898,566) (8,176,343)  
Total assets, net of depreciation and amortization 5,995,835           5,995,835   $ 4,150,906
International 5,995,835           5,995,835   $ 4,150,906
Capital expenditures 120,810           129,216    
Income tax (expense) benefit         (707)  
(Loss) income from operations (3) [3] (2,898,625)     (3,084,438)     (7,910,611) (8,190,427)  
Other income (4) [4] (713)     10,334     12,045 17,456  
Net (loss) income (2,899,338) $ (2,325,619) $ (2,673,608) (3,074,104) $ (2,673,179) $ (2,429,061) (7,898,566) (8,176,343)  
Net loss from continuing operations               (8,173,678)  
Loss from discontinued operations, net of tax               (2,665)  
UNITED STATES                  
Total assets, net of depreciation and amortization 5,879,053     4,819,050     5,879,053 4,819,050  
International 5,879,053     4,819,050     5,879,053 4,819,050  
Non-US [Member]                  
Total assets, net of depreciation and amortization 116,782     2,606     116,782 2,606  
International 116,782     2,606     116,782 2,606  
Royalty [Member]                  
Revenue from contract with customer 2,047     4,895     26,188 13,985  
License [Member]                  
Revenue from contract with customer 4,726         4,726 9,953  
Diagnostics Segment [Member]                  
Grant and other revenue 106,729     77,049     381,103 309,670  
Revenues, Total 113,502     81,944     412,017 333,608  
Cost of revenue 82     195     1,048 6,559  
Research and development expenses 1,251,383     1,678,423     3,402,160 3,194,468  
Selling, general and administrative expenses, excluding depreciation and amortization [1]          
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 4,027         4,027  
(Loss) income from operations (3) [3] (1,268,605)     (1,596,674)     (2,995,218) (2,867,419)  
Other expense (4) [4]          
Net (loss) income (1,141,990)     (1,596,746)     (2,995,218) (2,870,332)  
Capital expenditures 120,810           120,810    
Income tax (expense) benefit       (72)       (248)  
(Loss) income from operations (3) [3] (1,268,605)     (1,596,674)     (2,995,218) (2,867,419)  
Other income (4) [4]          
Net (loss) income (1,141,990)     (1,596,746)     (2,995,218) (2,870,332)  
Net loss from continuing operations               (2,867,667)  
Loss from discontinued operations, net of tax               (2,665)  
Diagnostics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 1,000     36,811     1,000 36,811  
International 1,000     36,811     1,000 36,811  
Diagnostics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 116,782     2,606     116,782 2,606  
International 116,782     2,606     116,782 2,606  
Diagnostics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer 2,047     4,895     26,188 13,985  
Diagnostics Segment [Member] | License [Member]                  
Revenue from contract with customer 4,726         4,726 9,953  
Therapeutics Segment [Member]                  
Grant and other revenue 154,887     154,867     283,745 204,919  
Revenues, Total 154,887     154,867     283,745 204,919  
Cost of revenue          
Research and development expenses 126,615     123,135     256,886 418,315  
Selling, general and administrative expenses, excluding depreciation and amortization [1]     1,052     (550) 15,828  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]          
(Loss) income from operations (3) [3] 28,272     30,680     27,409 (229,224)  
Other expense (4) [4]          
Net (loss) income 28,272     30,696     27,409 (229,244)  
Capital expenditures              
Income tax (expense) benefit       16       (20)  
(Loss) income from operations (3) [3] 28,272     30,680     27,409 (229,224)  
Other income (4) [4]          
Net (loss) income 28,272     30,696     27,409 (229,244)  
Net loss from continuing operations               (229,244)  
Loss from discontinued operations, net of tax                
Therapeutics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 38,320     93,860     38,320 93,860  
International 38,320     93,860     38,320 93,860  
Therapeutics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization          
International          
Therapeutics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer          
Therapeutics Segment [Member] | License [Member]                  
Revenue from contract with customer            
Corporate Segment [Member]                  
Grant and other revenue          
Revenues, Total          
Cost of revenue          
Research and development expenses          
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,773,532     1,484,155     4,895,328 4,985,990  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 11,375     34,289     47,474 107,794  
(Loss) income from operations (3) [3] (1,784,907)     (1,518,444)     (4,942,802) (5,093,784)  
Other expense (4) [4] (713)     10,334     12,045 17,456  
Net (loss) income (1,785,620)     (1,508,055)     (4,930,757) (5,076,767)  
Capital expenditures           8,406    
Income tax (expense) benefit       55       (439)  
(Loss) income from operations (3) [3] (1,784,907)     (1,518,444)     (4,942,802) (5,093,784)  
Other income (4) [4] (713)     10,334     12,045 17,456  
Net (loss) income (1,785,620)     (1,508,055)     (4,930,757) (5,076,767)  
Net loss from continuing operations               (5,076,767)  
Loss from discontinued operations, net of tax                
Corporate Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 5,839,733     4,688,379     5,839,733 4,688,379  
International 5,839,733     4,688,379     5,839,733 4,688,379  
Corporate Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization          
International          
Corporate Segment [Member] | Royalty [Member]                  
Revenue from contract with customer          
Corporate Segment [Member] | License [Member]                  
Revenue from contract with customer            
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($15,402 and $34,289 for the three-month periods ended September 30, 2020 and 2019, and $51,501 and $107,794 for the nine-month periods ended September 30, 2020 and 2019, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.